Park Medi World Limited reported a significant improvement in profitability for the first quarter of FY27, with consolidated net profit after tax (PAT) rising 35% year-on-year to ₹885.93 million. The growth was underpinned by a 19% surge in revenue from operations, which reached ₹4,757.09 million for the quarter ended June 30, 2026, compared to ₹3,988.45 million in the corresponding period of FY26. This performance highlights the company’s ability to drive top-line growth while expanding operational margins.

The Board of Directors approved the unaudited standalone and consolidated financial results on August 3, 2026, following recommendations from the Audit Committee. In compliance with Regulation 33 read with Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company published the results in ‘The Economic Times’ and ‘Navbharat Times’ on August 4, 2026. The financial statements were subjected to a limited review by the statutory auditor, who issued unmodified reports.

Financial Performance Overview

Key financial metrics for the quarter reflect robust operational execution across the company’s network of 17 hospitals and 4,290 beds. EBITDA increased by 20% year-on-year to ₹1,260.88 million, up from ₹1,049.31 million in Q1FY26. Profit before tax also saw substantial growth, rising to ₹1,050.84 million from ₹818.99 million in the previous year’s corresponding quarter.

On a sequential basis, revenue grew marginally by 3% compared to the fourth quarter of FY26, which stood at ₹4,604.13 million. However, EBITDA declined slightly quarter-on-quarter to ₹1,260.88 million from ₹1,273.68 million in Q4FY26, indicating some pressure on operating margins despite higher revenue. Net profit, however, improved sequentially by 15% to ₹885.93 million from ₹767.78 million.

What the Numbers Show

The divergence between EBITDA and PAT trends warrants attention. While EBITDA contracted slightly on a quarterly basis, net profit expanded significantly. This suggests that non-operating factors or lower tax provisions may have contributed to the bottom-line growth in Q1FY27 relative to Q4FY26. Year-on-year, both top-line and bottom-line metrics show strong momentum, with PAT growing faster than revenue, signaling improved operational leverage over the past year. The company’s focus on consolidation and continued execution across its hospital network appears to be yielding positive financial outcomes.

Park Medi World Limited has initiated a postal ballot to seek shareholder approval for altering the objects of its Initial Public Offer (IPO) proceeds. The company proposes to redirect INR 648.32 million in unutilised funds toward the acquisition of V3 Healthcare Private Limited, which operates The Medicity Hospital, Rudrapur. This strategic reallocation aims to accelerate revenue generation by deploying capital into an operational asset rather than continuing construction on partially funded projects. E-voting for the special resolution commenced on August 05, 2026, and concludes on September 03, 2026.

The move addresses the underutilisation of funds allocated to two original IPO objects: hospital development in NCR (Object 2) and medical equipment procurement (Object 3). As per the prospectus dated December 12, 2025, Park Medi World raised INR 7,700 million through a fresh issue and an offer for sale. After deducting issue expenses of INR 567.23 million, net proceeds amounted to INR 7,132.77 million. The company has already fully utilised funds for repayment of borrowings (INR 3,800 million) and unidentified inorganic acquisitions (INR 2,453.18 million).

IPO Proceeds Utilisation Status

The following table outlines the utilisation status of the IPO proceeds as disclosed in the postal ballot notice:

Proposed Variation: Acquisition of The Medicity Hospital

The Board of Directors approved the proposal on August 03, 2026, to combine the unutilised balances from Objects 2 and 3 — totalling INR 648.32 million — into a new Object 5. This amount will fund the capital expenditure for acquiring The Medicity Hospital, Rudrapur. The facility is a NABH-accredited, multi-super speciality institution with a capacity of 330 beds, situated on approximately 7,000 square meters of land with 1.64 lakh square feet of covered area.

Management argues that this acquisition represents a more efficient allocation of capital compared to the original timeline for the Rohtak hospital project. By shifting funds to an operational asset, the company expects to realise economic benefits sooner while maintaining a prudent capital structure. Term borrowings stood at INR 282 million as of March 31, 2026. The revised timeline for utilising the redirected funds is FY 2026-27.

Regulatory Compliance and Voting Process

The postal ballot notice was dispatched electronically on August 04, 2026, to shareholders registered as of the cut-off date, July 31, 2026. The voting process is facilitated through National Securities Depository Limited (NSDL). A newspaper advertisement confirming the dispatch was published on August 05, 2026, in ‘Financial Express’ and ‘Jansatta’, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Since more than 75% of the IPO proceeds have been utilised toward original objects, the conditions for an exit offer under Regulation 59 read with Schedule XX of the SEBI ICDR Regulations, 2018, do not apply. The results of the postal ballot are expected to be announced on or before September 07, 2026. No directors voted against the proposed variation.